Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2017-05-26 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Appointment of Joint Broker
Regulatory Filings Classification · 98% confidence The document is very short (2404 characters) and is identified by an 'RNS Number' (2980G) and dated May 26, 2017. The content announces a specific corporate action: the 'Appointment of Joint Broker' (Peel Hunt LLP). This is a specific, non-financial, material event announcement typically disseminated via regulatory news services. It does not fit the definitions for a full report (10-K, IR, AR), financial results (ER, MRQ), or management changes (MANG). Since it is a specific regulatory announcement that doesn't fit the other specialized codes (like DIRS, DIV, SHA), the most appropriate general regulatory category is 'Regulatory Filings' (RNS), as it is explicitly sourced from the 'RNS' service and reports a material event.
2017-05-26 English
Group of companies' accounts made up to 2016-12-31
Regulatory Filings
2017-05-11 English
Annual Report, Accounts and AGM Notification
AGM Information Classification · 98% confidence The document is very short (2872 characters) and explicitly states that copies of the '2016 Annual Report and Accounts' have been sent to shareholders and provides a link to the document. It also announces the date and location of the 'Annual General Meeting' (AGM). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that a report has been published or sent out, rather than being the full report itself, should be classified as a Report Publication Announcement (RPA). Since it announces both the publication of the Annual Report and the AGM details, RPA is the most fitting primary classification for the announcement itself, although AGM-R is also relevant for the meeting notice. Given the structure, RPA captures the essence of announcing the availability of the main report.
2017-04-28 English
Appointment of Chief Financial Officer
Board/Management Information Classification · 99% confidence The document is an official announcement released via RNS (RNS Number : 4510B) on April 4, 2017. The core content explicitly states the 'Appointment of Chief Financial Officer' (Joanne Estell) and details her background and start date. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2017-04-04 English
Preliminary Results for the Year Ended 31 Dec 2016
Earnings Release Classification · 99% confidence The document explicitly states: "Shield Therapeutics plc... today announces its preliminary Group results for the year ended 31 December 2016." It contains detailed financial highlights (Net loss, EPS, Net cash), operational achievements, and commentary from the Chairman and CEO regarding the full fiscal year performance. This content structure is characteristic of an Annual Report or the preliminary results announcement preceding the full 10-K filing. Since it covers the full year ended December 31, 2016, and provides comprehensive financial summaries, it aligns best with the Annual Report category (10-K). Although it is an announcement of preliminary results, the depth of financial data provided suggests it is the primary annual disclosure, rather than just a brief press release (ER). Given the context of US SEC filings, this is the equivalent of the information contained within a 10-K, even if filed under a different jurisdiction's rules (RNS number suggests UK listing). The presence of a Chairman's statement and CEO's statement further supports this classification over a simple Earnings Release (ER). FY 2016
2017-04-04 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is very short (2256 characters) and its primary purpose is to announce *when* the audited results for the year ended 31 December 2016 will be released (Tuesday 4 April 2017) and to invite analysts to a presentation/conference call on that day. It explicitly states 'Notice of Results'. According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement about the publication of a report, rather than the report itself, should be classified as a Report Publication Announcement (RPA). The presence of the RNS Number further confirms this is a regulatory announcement about an upcoming event/report.
2017-03-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.